Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | CPT2 | P23786 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16970940 | 0.87 | SMN1; SMN2 (0.30) | — | |
| SCHEMBL4143122 | 0.84 | LMNA (0.33) | CYP4F2CYP4A11 | |
| SCHEMBL1760755 | 0.84 | SMN1; SMN2 (0.32) | — | |
| SCHEMBL6448246 | 0.79 | SMN1; SMN2 (0.42) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL7698561 | 0.78 | ALDH1A1 (0.43) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL20438000 | 0.77 | TDP1 (0.46) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL20437994 | 0.77 | TDP1 (0.46) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL15297874 | 0.77 | TDP1 (0.46) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL20438002 | 0.77 | TDP1 (0.46) | CYP4F2CYP4A11FFAR1CPT2TDP1 | |
| SCHEMBL10025732 | 0.75 | ALDH1A1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1056716-B1 | CYCLOHEXANEDIOLE DERIVATIVES | BASILEA PHARMACEUTICA AG (CH) | 2002-12-11 | — | — | EP | disclosed |
| US-6184422-B1 | TREATMENT AND PREVENTION OF HYPERPROLIFERATIVE SKIN DISEASES; REVERSING CONDITIONS ASSOCIATED WITH PHOTODAMAGE; ANTITUMOR, -CARCINOGENIC AGENTS; PSORIASIS; DISORDERS OF NEOPLASTIC DISEASES; KERATINIZATION/KERATOSIS; ACNE; SEBORRHEA | HOFFMAN-LA ROCHE INC. | 2001-02-06 | — | — | US | disclosed |